Bioatla Inc Up 15.61% To $3.48 After Earnings Beat

Bioatla Inc (BCAB) said after close Tuesday that it lost $0.56 per share in quarter four 2023. The company reported $0.00 in revenue

In the same quarter a year ago, the company lost $0.63 per share on revenue of $0.00.

The stock is up 15.61% to $3.48 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Bioatla Inc has been a strong performer over the past few months, garnering a high Long-Term Technical Rank by InvestorsObserver of 77, putting Bioatla Inc in the top 25% of stocks. The firm set a 52-week low on October 25, 2023 at $1.24 and set a 52-week high on May 15, 2023 at $4.07.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.